Shojaee F, Azadian E, Wong MX, Ma X, Rickard J, Pang J, Hall C, Kueh AJ, Masters SL, Rioja I, Prinjha RK, Doerflinger M, Lawlor KE, Rashidi M, Vince JE. NLRP3 inflammasome–driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors. Science Advances. 2025;11(28):10.1126/sciadv.adv0079
M. Bader S, Scherer L, Schaefer J, Cooney JP, Mackiewicz L, Dayton M, Georgy SR, Davidson KC, Allison CC, Herold MJ, Strasser A, Pellegrini M, Doerflinger M. IL-1β drives SARS-CoV-2-induced disease independently of the inflammasome and pyroptosis signalling. Cell Death & Differentiation. 2025;32(7):10.1038/s41418-025-01459-x
Cooney JP, Hirons A, Jansz N, Allison CC, Hickey P, Teh CE, Tan T, Dagley LF, Yousef J, Yurick D, Khoury G, Preston SP, Arandjelovic P, Davidson KC, Williams LJ, Bader SM, Wang L, Bhandari R, Mackiewicz L, Dayton M, Clow W, Faulkner GJ, Gray DH, Einsiedel L, Purcell DFJ, Doerflinger M, Pellegrini M. Combination antiretroviral therapy and MCL-1 inhibition mitigate HTLV-1 infection in vivo. Cell. 2025;:10.1016/j.cell.2025.06.023
Renz A, Hohner M, Jami R, Breitenbach M, Josephs-Spaulding J, Dürrwald J, Best L, Dulière V, Mialon C, Bader SM, Marinos G, Leonidou N, Cabreiro F, Pellegrini M, Doerflinger M, Rosa-Calatrava M, Pizzorno A, Dräger A, Schindler M, Kaleta C. Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral drugs against RNA viruses. Communications Biology. 2025;8(1):10.1038/s42003-025-08148-y
M. Bader S, Calleja DJ, Devine SM, Kuchel NW, Lu BGC, Wu X, Birkinshaw RW, Bhandari R, Loi K, Volpe R, Khakham Y, Au AE, Blackmore TR, Mackiewicz L, Dayton M, Schaefer J, Scherer L, Stock AT, Cooney JP, Schoffer K, Maluenda A, Kleeman EA, Davidson KC, Allison CC, Ebert G, Chen G, Katneni K, Klemm TA, Nachbur U, Georgy SR, Czabotar PE, Hannan AJ, Putoczki TL, Tanzer M, Pellegrini M, Lechtenberg BC, Charman SA, Call MJ, Mitchell JP, Lowes KN, Lessene G, Doerflinger M, Komander D. A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID. Nature Communications. 2025;16(1):10.1038/s41467-025-57905-4
Reynolds GK, Williams L, Anderson MA, Dowling MR, Minson A, Dickinson MJ, Thursky KA, Harrison SJ, Slavin MA, Doerflinger M, Teh BW. Predicting Risk of Infection in Patients Receiving CAR-T for Aggressive Lymphoma: A Study Exploring the Utility of Immune Profiling. Blood. 2024;144(Supplement 1):10.1182/blood-2024-203133
Reynolds GK, Williams L, Anderson MA, Dowling MR, Minson A, Dickinson MJ, Thursky KA, Harrison SJ, Slavin MA, Doerflinger M, Teh BW. Longitudinal Cytokine Expression in Aggressive Lymphoma Patients Treated with CAR-T: Applications of Immune Profiling to CAR-T. Blood. 2024;144(Supplement 1):10.1182/blood-2024-202836
Wang TT, Hirons A, Doerflinger M, Morris KV, Ledger S, Purcell DFJ, Kelleher AD, Ahlenstiel CL. Current State of Therapeutics for HTLV-1. Viruses. 2024;16(10):10.3390/v16101616
Muhi S, Buultjens AH, Porter JL, Marshall JL, Doerflinger M, Pidot SJ, O’Brien DP, Johnson PDR, Lavender CJ, Globan M, McCarthy J, Osowicki J, Stinear TP. Mycobacterium ulcerans challenge strain selection for a Buruli ulcer controlled human infection model. PLOS Neglected Tropical Diseases. 2024;18(5):10.1371/journal.pntd.0011979
M. Bader S, Cooney JP, Bhandari R, Mackiewicz L, Dayton M, Sheerin D, Georgy SR, Murphy JM, Davidson KC, Allison CC, Pellegrini M, Doerflinger M. Necroptosis does not drive disease pathogenesis in a mouse infective model of SARS-CoV-2 in vivo. Cell Death & Disease. 2024;15(1):10.1038/s41419-024-06471-6
